Abstract
Purpose
Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients. We conducted a prospective study to assess the utility of teneligliptin for diabetic patients undergoing hemodialysis.
Methods
Blood glucose, glycated albumin, and HbA1c were measured every 4 weeks, at 4, 12, 20, and 28 weeks, and every 8 weeks, respectively, for patients treated with teneligliptin (n = 14; 7 patients newly started and 7 that switched from other medications) and patients of a control group who continued ongoing antidiabetic therapy (n = 29).
Results
Blood glucose level showed a 36.7 mg/dl decrease from 4 weeks in the teneligliptin group (p < 0.05). The differences in glycated albumin (at 28 w) and HbA1c (at 24 w) between the teneligliptin group and the control group were −3.1 % (p < 0.05) and −0.57 % (p = 0.057), respectively. These parameters also decreased in patients who switched from voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd after teneligliptin administration. No case with hypoglycemia was identified. One patient had the dose of a laxative administered for constipation increased; however, no patient ceased teneligliptin due to side effects.
Conclusion
Teneligliptin 20 mg is well tolerated, safe, and significantly improves glycemic control in diabetic patients with end-stage renal disease. Teneligliptin 20 mg once daily was considered to be more potent than voglibose 0.2 mg t.i.d. or vildagliptin 50 mg qd.
Similar content being viewed by others
References
Bouchi R, Babazono T, Yoshida N et al (2010) Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes. Hypertens Res 33:1298–1304
Freedman BI, Andries L, Shihabi ZK et al (2011) Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 6:1635–1643
Fukuoka K, Nakao K, Morimoto H et al (2008) Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 13:278–283
Inaba M, Maekawa K, Okuno S et al (2012) Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 78:273–280
Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R (2010) Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 5:1595–1601
Feldt-Rasmussen B (2006) Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int 70:1392–1394
Inaba M, Okuno S, Kumeda Y et al (2007) Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 18:896–903
Kishimoto M (2013) Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 6:187–195
Peacock TP, Shihabi ZK, Bleyer AJ et al (2008) Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 73:1062–1068
Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W (2011) Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 13:947–954
Eto T, Inoue S, Kadowaki T (2012) Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 14:1040–1046
Regeur L, Faber OK, Binder C (1978) Plasma C-peptide in uraemic patients. Scand J Clin Lab Invest 38:771–775
Robaudo C, Zavaroni I, Garibotto G, Deferrari G (1996) Renal metabolism of C-peptide in patients with early insulin-dependent diabetes mellitus. Nephron 72:395–401
Gallwitz B (2007) Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs Today (Barc) 43:801–814
Monami M, Iacomelli I, Marchionni N, Mannucci E (2010) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 20:224–235
Conflict of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Otsuki, H., Kosaka, T., Nakamura, K. et al. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol 46, 427–432 (2014). https://doi.org/10.1007/s11255-013-0552-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-013-0552-6